AL · State regulatory reference

Alabama.

Restrictive

Alabama's Telehealth Medical Services Act (Ala. Code § 34-24-701 et seq., 2022) permits forming a physician-patient relationship and prescribing legend drugs entirely via telehealth, but the state is aggressive on compounded GLP-1s. The Board of Pharmacy and Board of Medical Examiners prohibit compounding with semaglutide salt forms, research-grade, or any non-pharmaceutical-grade/non-FDA-registered API. This is backed by real enforcement: on November 10, 2025, Attorney General Steve Marshall sued a Cullman clinic (Aurora IV and Wellness) for injecting patients with research-grade tirzepatide and semaglutide marketed as 'pharmaceutical-grade,' obtaining a temporary restraining order and asset freeze.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Alabama Medical Board

https://www.albme.gov/ ↗

Pharmacy board

Alabama Board of Pharmacy

https://albop.com/ ↗

TPC notes

Telehealth

Under § 34-24-701 et seq., a physician-patient relationship may be established via synchronous telehealth without a prior in-person exam and legend drugs may be prescribed; controlled substances additionally require synchronous audio/audio-visual contact plus an in-person encounter within the preceding 12 months.

Compounding

The Board of Pharmacy (echoed by the Board of Medical Examiners) prohibits compounding semaglutide from salt forms, research-grade, or non-pharmaceutical-grade API not from an FDA-registered establishment, and requires USP compliance; the November 2025 AG suit against a Cullman med spa over research-grade GLP-1s shows active enforcement.

Sources